FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy

KENILWORTH, N.J.--(Healthcare Sales & Marketing Network)--Merck (MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (... Biopharmaceuticals, Oncology, FDA Merck, KEYTRUDA, pembrolizumab, Hodgkin lymphoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news